Milnacipran for Chronic pain in the orofacial region

Clinical Neuropharmacology

Volumn 33, Issue 5, 2010, Pages 270-

  Pae, Chi Un ^a,b  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DULOXETINE; MILNACIPRAN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CHRONIC PAIN; CLINICAL PRACTICE; DOSE RESPONSE; ENZYME ACTIVITY; FACE PAIN; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; FACIAL PAIN; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 77958008979     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181f5169d     Document Type: Letter

References (7)

1. Ito M, Kimura H, Yoshida K, et al. Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region. Clin Neuropharmacol 2010;33:79Y83.
2. Pae CU, Marks DC, Han C, et al. Duloxetine: an emerging evidence for fibromyalgia. Biomed Pharmacother 2009;63:69Y71.
3. Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: a premise and promise. Psychiatry Investig 2008;5:142Y147.
4. Pae CU, Marks DM, Shah M, et al. Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol 2009;32:355Y363.
5. Obata H, Saito S, Koizuka S, et al. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain. Anesth Analg 2005;100:1406Y1410.
6. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32: 1975Y1985.
7. Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19(Suppl 1): S27YS35.